Healthcare Resource Utilization and Costs Among Adolescent Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): A US Administrative Claims Database Study
Author(s)
Sophie Guillonneau, MS1, Emma Etcheverry, MS1, Natalia Petruski-Ivleva, PhD2, Ryan Thomas, MS, PharmD3, Scott Nash, M.D.3, A. Radwan, MA MBBChir FFPM3, Sabrina Solouki, PhD2, Mark Corbett, M.D.2, Aakash Bipin Gandhi, PhD2;
1Sanofi, Gentilly, France, 2Sanofi, Cambridge, MA, USA, 3Regeneron Pharmaceuticals inc., Sleepy Hollow, NY, USA
1Sanofi, Gentilly, France, 2Sanofi, Cambridge, MA, USA, 3Regeneron Pharmaceuticals inc., Sleepy Hollow, NY, USA
Presentation Documents
OBJECTIVES: To describe the economic burden of chronic rhinosinusitis with nasal polyps (CRSwNP) among adolescent patients in the US.
METHODS: This retrospective study analyzed claims data from Optum’s de-identified Clinformatics® Data Mart Database between January 1, 2019, and April 1, 2023. Eligible patients (12-17 years old) had ≥1 claim with CRS-related (J32.X) and NP-related (J33.X) ICD-10 codes, or ≥2 NP-related claims, occurring ≥30 days apart (Index date on second claim). Patients were required to have 12 months of continuous insurance enrollment both prior to (baseline) and following (follow-up) the index date. Patient demographics, comorbidities, and prior treatments were described at baseline. Healthcare resource utilization and costs were then described during the 12-month follow-up for the study population and a subgroup of treated patients with systemic corticosteroids or functional endoscopic sinus surgery (FESS) at baseline. Descriptive statistics were used to summarize continuous and categorical variables.
RESULTS: Overall, 538 adolescent patients (mean [SD] age, 15.0 [1.7]; 62.8% male; 66.2% with inadequately controlled disease) were included. At baseline, allergic rhinitis (70.1%) and asthma (39.4%) were the most prevalent type 2 comorbidities. FESS was performed in 26.2% of patients, and 53.5% received oral corticosteroids at baseline. During 12-months follow-up, proportion of patients with an all-cause inpatient hospitalization (5% vs 3.7%) and otolaryngologist (75.3% vs 69.5%) visit were observed to be higher in the treated subgroup compared to the total study population. Median annual all-cause healthcare costs ($9,145 vs $8,046) were higher for the previously treated subgroup compared to the total study population with differences observed in median cost for outpatient visits ($4,202 vs $3,809) and prescription drug fills ($433 vs $339), respectively.
CONCLUSIONS: Economic burden among adolescents with CRSwNP varied by prior treatment status and the HcRU point of service assessed. Future work should compare the economic burden of CRSwNP among adolescents to those without the disease.
METHODS: This retrospective study analyzed claims data from Optum’s de-identified Clinformatics® Data Mart Database between January 1, 2019, and April 1, 2023. Eligible patients (12-17 years old) had ≥1 claim with CRS-related (J32.X) and NP-related (J33.X) ICD-10 codes, or ≥2 NP-related claims, occurring ≥30 days apart (Index date on second claim). Patients were required to have 12 months of continuous insurance enrollment both prior to (baseline) and following (follow-up) the index date. Patient demographics, comorbidities, and prior treatments were described at baseline. Healthcare resource utilization and costs were then described during the 12-month follow-up for the study population and a subgroup of treated patients with systemic corticosteroids or functional endoscopic sinus surgery (FESS) at baseline. Descriptive statistics were used to summarize continuous and categorical variables.
RESULTS: Overall, 538 adolescent patients (mean [SD] age, 15.0 [1.7]; 62.8% male; 66.2% with inadequately controlled disease) were included. At baseline, allergic rhinitis (70.1%) and asthma (39.4%) were the most prevalent type 2 comorbidities. FESS was performed in 26.2% of patients, and 53.5% received oral corticosteroids at baseline. During 12-months follow-up, proportion of patients with an all-cause inpatient hospitalization (5% vs 3.7%) and otolaryngologist (75.3% vs 69.5%) visit were observed to be higher in the treated subgroup compared to the total study population. Median annual all-cause healthcare costs ($9,145 vs $8,046) were higher for the previously treated subgroup compared to the total study population with differences observed in median cost for outpatient visits ($4,202 vs $3,809) and prescription drug fills ($433 vs $339), respectively.
CONCLUSIONS: Economic burden among adolescents with CRSwNP varied by prior treatment status and the HcRU point of service assessed. Future work should compare the economic burden of CRSwNP among adolescents to those without the disease.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE107
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin)